Regulatory Approval Validates Molecular Iodine’s Remarkable Capabilities to Improve Healthcare & Patient Outcomes

I2Pure, a leader in molecular iodine technology, today celebrates Zimmer Biomet’s recent achievement in receiving Japan's Pharmaceutical and Medical Devices Agency (PMDA) approval for orthopedic implants utilizing iodine technology to inhibit bacterial adhesion on implant surfaces.

This milestone represents further validation of molecular iodine's therapeutic potential in advanced medical applications. “We could not be more pleased to see Zimmer Biomet and the Japan PDMA recognize iodine as a biocompatible, essential body nutrient - a characterization that underscores the inherent biological compatibility and safety profile that makes molecular iodine an ideal candidate for infection prevention strategies,” said Ilker Bayer, I2Pure’s Chief Scientist.

"The approval of iodine as an implant coating marks a watershed moment for molecular iodine applications in medical care," said Jeff Jochims, CEO at I2Pure. "This approval by a leading regulatory agency validates what we've long known: that molecular iodine offers unique advantages for infection management without contributing to antibiotic resistance. We’re excited to see a leading multinational manufacturer like Zimmer Biomet championing the inherent capabilities of molecular iodine for broader healthcare applications."

The characterization of iodine as an "essential body nutrient" highlights a critical advantage in the fight against hospital-acquired and surgical-site infections. Unlike antibiotics, which contribute to the expansion of drug resistance or suffer the limitations of antibiotic allergies, molecular iodine is an essential nutrient for humans that is simultaneously a powerful antimicrobial that destroys the cellular structure and lifecycle of pathogens, resulting in broad-spectrum efficacy with no known resistance formation.

Advancing Molecular Iodine Innovation; Presenting at AAHKS

I2Pure specializes in developing technology and products for the delivery of molecular iodine across multiple medical indications. The company's platform is designed to harness iodine's antimicrobial properties while leveraging its 200+ years of pharmacovigilance for efficacy and safety. I2Pure will present at the American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting October 24-25 in Booth 1441. At AAHKS, I2Pure will introduce several new products, including a topical iodine soak, an iodinated hand sanitizer, and a nasal decolonization swab kit. All interested parties are invited to visit Booth 1441 to meet members of our leadership team and to learn more about our technologies and products.

About I2Pure: I2Pure is an iodine technology company dedicated to advancing health and biosafety through its patented, non-toxic molecular iodine solutions. I2Pure’s mission is to prevent pathogenic threats to the world. Our technology can be utilized for countless applications across healthcare, industrial biosafety, consumer products, and food processing. The platform technology can be delivered directly or through carriers via solutions, nano particles, polymers and coatings.

For more information about I2Pure, visit https://www.i2pure.com or contact the company at info@i2pure.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251006477124/en/